Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 58 of 110 Updated Nov 17, 2026

Follistatin 315

FS-315

PRECLINICAL · FOLLISTATIN ISOFORM; ANABOLIC

▓ 43 indexed citations across PubMed (21), EuropePMC (22).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

43 citations across 3 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Circulating follistatin; heparin-binding; systemic myostatin inhibition

Researched effects

Systemic myostatin inhibition; lean mass preservation

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

100-500 mcg SC daily

Known concerns

Reproductive hormone interference

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles.

    The Journal of clinical endocrinology and metabolism · 2001 — CLINICAL TRIALS · AUTHORITY 71.1

  2. Regulation of ovarian function by the TGF-beta superfamily and follistatin.

    Reproduction (Cambridge, England) · 2003 — REVIEWS · AUTHORITY 52.3

  3. Follistatin and its role as an activin-binding protein.

    The journal of medical investigation : JMI · 1997 — REVIEWS · AUTHORITY 52.0

  4. Increased activin bioavailability enhances hepatic insulin sensitivity while inducing hepatic steatosis in male mice.

    Endocrinology · 2013 — RESEARCH ARTICLES · AUTHORITY 37.3

  5. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin.

    Endocrinology · 1991 — RESEARCH ARTICLES · AUTHORITY 36.0

  6. Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  7. Follistatin Forms a Stable Complex With Inhibin A That Does Not Interfere With Activin A Antagonism.

    2023 — RESEARCH ARTICLES · AUTHORITY 34.3

  8. Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice.

    2021 — RESEARCH ARTICLES · AUTHORITY 34.1

  9. Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function.

    2021 — RESEARCH ARTICLES · AUTHORITY 34.1

  10. Detection of black market follistatin 344.

    Drug testing and analysis · 2019 — RESEARCH ARTICLES · AUTHORITY 33.9

Full citation library

Year distribution

Clinical Trials

1
  1. 1.

    Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, et al. · The Journal of clinical endocrinology and metabolism · 2001 · PMID 11549651

    To further explore the developmental dynamics and possible roles of inhibin, activin, and follistatin in the development of human antral follicles as well as the relationship between mRNA and protein levels of these hormones within follicles, quantitative competitive RT-PCR assays were established to determine mRNA levels for the inhibin/activin subunits and both follistatin splice variants. Granulosa cell RNA was obtained by transvaginally aspirating follicles (6-23 mm) from carefully character…

Reviews

2
  1. 2.

    Sugino H, Sugino K, Hashimoto O, Shoji H, et al. · The journal of medical investigation : JMI · 1997 · PMID 9395712

    Follistatin (FS), a specific binding protein for activin, neutralizes the diverse actions of activin by forming an inactive complex with activin. FS is a monomer derived from two polypeptide core sequences of 288 (FS-288) and 315 (FS-315) amino acids originated from alternatively spliced mRNA. We purified six molecular forms of FS from porcine ovaries. Their structural differences were caused by truncation of the COOH-terminal region and/or the presence of carbohydrate chains, resulting in the f…

  2. 3.

    Lin SY, Morrison JR, Phillips DJ, de Kretser DM · Reproduction (Cambridge, England) · 2003 · PMID 12887271

    The role of follistatin as an activin-binding protein has dominated the study of this molecule for the last 10 years. However, there is emerging evidence that follistatin has a role in modulating the biology of other members of the transforming growth factor beta (TGF-beta) superfamily. This review summarizes the current concepts encompassing follistatin biochemistry as well as molecules with which it is functionally associated. Moreover, the importance of the two follistatin isoforms (follistat…

Research Articles

40
  1. 4.

    Reichel C, Gmeiner G, Thevis M · Drug testing and analysis · 2019 · PMID 31758732

    Follistatin, a myostatin-inhibiting protein, is prohibited according to chapter S4 of the "WADA 2019 List of Prohibited Substances and Methods". While currently no approved pharmaceutical formulations of follistatin are available, follistatin can be bought on the black market. Most of the products are labeled "follistatin 344" (FS344), a few "follistatin 315". A study on FS344 black market products was performed and an electrophoretic detection method for serum and urine developed. While only ni…

  2. 5.

    Kawakami S, Fujii Y, Winters SJ · Molecular and cellular endocrinology · 2001 · PMID 11165049

    Activin and follistatin (FS) appear to play a role in the development of the skin and its appendages, in the inflammatory process, angiogenesis, and in wound healing. Although there is information on the expression of activin subunits and receptors in fibroblasts and keratinocytes, there are no reports on the regulation of FS expression in these cells. In the present study we analyzed the splicing variants of FS mRNAs in fibroblasts from genital and nongenital skin by RT-PCR and northern analysi…

  3. 6.

    Inouye S, Guo Y, DePaolo L, Shimonaka M, et al. · Endocrinology · 1991 · PMID 1906804

    Follistatin is a glycosylated monomeric protein originally isolated from ovarian follicular fluid based on its ability to specifically inhibit pituitary FSH release. To further explore the physiological role of follistatin, we have expressed recombinant human follistatins with 315 (rhFS-315) and 288 (rhFS-288) amino acids in Chinese hamster ovary cells under the control of the simian virus-40 promoter. The two types of FS originated from alternatively spliced mRNAs and rhFS-315 differed from rhF…

  4. 7.

    Saleh M, Garcia S, Mercer JE, Findlay JK · Journal of molecular endocrinology · 1994 · PMID 7893350

    Seven bovine follistatin (FS) cDNA clones were isolated from a bovine ovarian follicle cDNA library. The predicted amino acid sequences revealed that six of the cDNA clones represented an FS precursor of 344 amino acids which corresponded to a mature FS of 315 amino acids (FS 315), with one cDNA clone containing the entire coding sequence including 180 nucleotides of 5' untranslated sequence. The predicted amino acid sequence of the seventh cDNA clone, which differed in the 3' coding sequence, r…

  5. 8.

    Sugino K, Kurosawa N, Nakamura T, Takio K, et al. · The Journal of biological chemistry · 1993 · PMID 8340384

    Follistatin (FS), an activin-binding protein, is a monomer derived from two polypeptide core sequences of 315 (FS-315) and 288 (FS-288) amino acids originated from alternatively spliced mRNA. To define the structural heterogeneity of native FS, we purified six molecular forms of FS from porcine ovaries. Protein chemical analysis revealed that the structural differences among the six isoforms were caused by truncation of the carboxyl-terminal region and/or the presence of carbohydrate chains, res…

  6. 9.

    Holdsworth-Carson SJ, Craythorn RG, Winnall WR, Dhaliwal K, et al. · Reproduction, fertility, and development · 2015 · PMID 24630125

    Female mice lacking the follistatin gene but expressing a human follistatin-315 transgene (tghFST315) have reproductive abnormalities (reduced follicles, no corpora lutea and ovarian-uterine inflammation). We hypothesised that the absence of follistatin-288 causes the abnormal reproductive tract via both developmental abnormalities and abnormal ovarian activity. We characterised the morphology of oviducts and uteri in wild type (WT), tghFST315 and follistatin-knockout mice expressing human folli…

  7. 10.

    Hashimoto O, Kawasaki N, Tsuchida K, Shimasaki S, et al. · Cellular signalling · 2000 · PMID 11027950

    We demonstrate the difference between the follistatin isoforms (FS-288 and FS-315), two activin-binding proteins, in the neutralizing activity for activin signalling. Transcriptional reporter assay using 3TP-Lux, an activin-responsive reporter construct, showed that the inhibitory effect of FS-288 on activin-induced transcriptional response is more potent than that of FS-315. The potency was not influenced by the presence of heparan sulfates, by which FS, in particular FS-288, associates with ce…

  8. 11.

    Hashimoto O, Nakamura T, Shoji H, Shimasaki S, et al. · The Journal of biological chemistry · 1997 · PMID 9153241

    There are two types of the activin-binding protein follistatin (FS), FS-288 and FS-315. These result from alternative splicing of mRNA. FS-288 exhibits high affinity for cell-surface heparan sulfate proteoglycans, whereas FS-315 shows low affinity. To understand the physiological role of cell-associated FS, we investigated the binding of activin to cell-associated FS and its behavior on the cell surface using primary cultured rat pituitary cells. Affinity cross-linking experiments using 125I-act…

  9. 12.

    Takamura K, Tsuchida K, Miyake H, Tashiro S, et al. · Hepato-gastroenterology · 2005 · PMID 15782995

    Activin A is an autocrine inhibitor of cell growth in the liver. The biological activity of activin A is mediated by a heteromeric receptor complex. Follistatin (FS) binds to activin and inhibits its biological effects, and acts as a negative regulator of muscle cells. The role of activin receptors during liver regeneration following a hepatectomy has not been fully assessed. This study investigates the mechanism underlying how activin receptors regulate hepatocyte growth, and the effects of int…

  10. 13.

    Necela BM, Su W, Thompson EA · The Journal of biological chemistry · 2008 · PMID 18768463

    Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) down-regulates the expression of follistatin mRNA in intestinal epithelial cells in vivo. The mechanism of PPARgamma-mediated down-regulation of follistatin was investigated using non-transformed, rat intestinal epithelial cells (RIE-1). RIE cells expressed activin A, the activin receptors ActRI and ActRII, and the follistatin-315 mRNA. RIE-1 cells responded to endogenous activin A, and this response was antagonized by fo…

  11. 14.

    Li MD, DePaolo LV, Ford JJ · Biology of reproduction · 1997 · PMID 9209088

    Expression of the follistatin (FS) and inhibin/activin (I/A) alpha, beta(A), and beta(B) subunit genes in porcine ovarian follicles was evaluated by reverse transcriptase polymerase chain reaction and/or RNase protection procedures to establish changes during the final stages of follicular development. For the I/A alpha and beta(A) subunits, expression increased (p < 0.05) as follicles progressed to the mid-stage of the follicular phase. The beta(B) subunit was expressed in lower concentrations,…

  12. 15.

    Yamane Y, Tohno-oka R, Yamada S, Furuya S, et al. · The Journal of biological chemistry · 1998 · PMID 9516434

    Enzymatic elimination of heparan sulfate (HS) causes abnormal mesodermal and neural formation in Xenopus embryos, and HS plays an indispensable role in establishing the embryogenesis and tissue morphogenesis during early Xenopus development (Furuya, S., Sera, M., Tohno-oka, R., Sugahara, K., Shiokawa, K., and Hirabayashi, Y. (1995) Dev. Growth Differ. 37, 337-346). In this study, HS was purified from Xenopus embryos to investigate its disaccharide composition and binding ability to basic fibrobl…

  13. 16.

    Ungerleider NA, Bonomi LM, Brown ML, Schneyer AL · Endocrinology · 2013 · PMID 23533219

    The development of insulin resistance is tightly linked to fatty liver disease and is considered a major health concern worldwide, although their mechanistic relationship remains controversial. Activin has emerging roles in nutrient homeostasis, but its metabolic effects on hepatocytes remain unknown. In this study, we investigated the effects of increased endogenous activin bioactivity on hepatic nutrient homeostasis by creating mice with inactivating mutations that deplete the circulating acti…

  14. 17.

    Fahmy-Garcia S, Farrell E, Witte-Bouma J, Robbesom-van den Berge I, et al. · Frontiers in bioengineering and biotechnology · 2019 · PMID 30881954

    The use of biomaterials and signaling molecules to induce bone formation is a promising approach in the field of bone tissue engineering. Follistatin (FST) is a glycoprotein able to bind irreversibly to activin A, a protein that has been reported to inhibit bone formation. We investigated the effect of FST in critical processes for bone repair, such as cell recruitment, osteogenesis and vascularization, and ultimately its use for bone tissue engineering.

  15. 18.

    Datta-Mannan A, Yaden B, Krishnan V, Jones BE, et al. · The Journal of pharmacology and experimental therapeutics · 2013 · PMID 23249626

    Human follistatin is a regulatory glycoprotein with widespread biologic functions, including antiinflammatory activities, wound-healing properties, and muscle-stimulating effects. The role of follistatin in a wide range of biologic activities shows promise for potential clinical application, which has prompted considerable interest in the investigation of the protein as a potential disease-modifying agent. In spite of this potential, the development of follistatin as a broad use biotherapeutic h…

  16. 19.

    Datta-Mannan A, Huang L, Pereira J, Yaden B, et al. · Drug metabolism and disposition: the biological fate of chemicals · 2015 · PMID 26354950

    Follistatin 315 heparan sulfate-binding deficient mutant human IgG4 Fc fusion (FST-ΔHBS-Fc) is a follistatin (FST) based Fc fusion protein currently being developed as a novel therapy for several potential indications, including muscle wasting. Previous assessments of the pharmacokinetics and therapeutic activity of FST-ΔHBS-Fc have shown a close association of the exposure-response relationship. The current work builds upon these initial studies by investigating the glycosylation characteristic…

  17. 20.

    Evans LW, Muttukrishna S, Groome NP · The Journal of endocrinology · 1998 · PMID 9518873

    Recent studies have found follistatin to be an important regulator of activin bioactivity. Whilst a number of assay formats have been described, all are of limited sensitivity and require the use of isotopes. Many use polyclonal antibodies. Furthermore, a wide range of follistatin preparations have been used as standards, complicating inter-laboratory comparison. We now describe an ultra-sensitive two-site enzyme immunoassay using a pair of mouse monoclonal antibodies raised against follistatin…

  18. 21.

    Kobayashi T, Niimi S, Hashimoto O, Hayakawa T · Biological & pharmaceutical bulletin · 2000 · PMID 10864030

    Follistatin (FS, an activin-binding protein) and activin A (homodimer of inhibin betaA chain) promote and inhibit cell proliferation in rat liver, respectively. The roles of activin AB (heterodimer of inhibin betaA and betaB) and activin B (homodimer of inhibin betaB) in rat liver have not been elucidated yet. In this study, we examined, by reverse-transcriptase polymerase chain reaction (RT-PCR) analysis, whether the levels of FS, inhibin betaA and betaB mRNAs change in the carbon tetrachloride…

  19. 22.

    Rostamitehrani Z, Javed R, Popplewell L. · 2025 · PMID 41283440

    Duchenne muscular dystrophy (DMD), which results from mutations that disrupt the expression of dystrophin proteins, is characterized by progressive muscle fiber wasting and the development of skeletal muscle fibrosis. The severe pathology leads to loss of ambulation, respiratory insufficiency, cardiomyopathy, and early death in patients. Dystrophin-focused therapies based on adeno-associated viral (AAV) vector-mediated gene addition, antisense oligonucleotide-induced repair of the transcript rea…

  20. 23.

    Schumann C, Nguyen DX, Norgard M, Bortnyak Y, Korzun T, Chan S, Lorenz AS, Moses AS, Albarqi HA, Wong L, Michaelis K, Zhu X, Alani AWG, Taratula OR, Krasnow S, Marks DL, Taratula O. · 2018 · PMID 30555546

    Muscle atrophy occurs during chronic diseases, resulting in diminished quality of life and compromised treatment outcomes. There is a high demand for therapeutics that increase muscle mass while abrogating the need for special dietary and exercise requirements. Therefore, we developed an efficient nanomedicine approach capable of increasing muscle mass. <b>Methods:</b> The therapy is based on nanoparticle-mediated delivery of follistatin messenger RNA (mRNA) to the liver after subcutaneous admin…

  21. 24.

    Kappes EC, Kattamuri C, Czepnik M, Yarawsky AE, Brûlé E, Wang Y, Ongaro L, Herr AB, Walton KL, Bernard DJ, Thompson TB. · 2023 · PMID 36718082

    Inhibins are transforming growth factor-β family heterodimers that suppress follicle-stimulating hormone (FSH) secretion by antagonizing activin class ligands. Inhibins share a common β chain with activin ligands. Follistatin is another activin antagonist, known to bind the common β chain of both activins and inhibins. In this study, we characterized the antagonist-antagonist complex of inhibin A and follistatin to determine if their interaction impacted activin A antagonism. We isolated the inh…

  22. 25.

    Chan ASM, McGregor NE, Poulton IJ, Hardee JP, Cho EH, Martin TJ, Gregorevic P, Sims NA, Lynch GS. · 2021 · PMID 33869993

    The development of the musculoskeletal system and its maintenance depends on the reciprocal relationship between muscle and bone. The size of skeletal muscles and the forces generated during muscle contraction are potent sources of mechanical stress on the developing skeleton, and they shape bone structure during growth. This is particularly evident in hypermuscular global myostatin (Mstn)-<i>null</i> mice, where larger muscles during development increase bone mass and alter bone shape. However,…

  23. 26.

    Fung RSK, Jin B, He M, Yuen KWY, Wong AOL. · 2017 · PMID 28883808

    Activin is involved in pituitary hormone regulation and its pituitary actions can be nullified by local production of its binding protein follistatin. In our recent study with grass carp, local release of growth hormone (GH) was shown to induce activin expression at pituitary level, which in turn could exert an intrapituitary feedback to inhibit GH synthesis and secretion. To further examine the activin/follistatin system in the carp pituitary, grass carp follistatin was cloned and confirmed to…

  24. 27.

    Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. · 2009 · PMID 19208403

    In most cases, pharmacologic strategies to treat genetic muscle disorders and certain acquired disorders, such as sporadic inclusion body myositis, have produced modest clinical benefits. In these conditions, inhibition of the myostatin pathway represents an alternative strategy to improve functional outcomes. Preclinical data that support this approach clearly demonstrate the potential for blocking the myostatin pathway. Follistatin has emerged as a powerful antagonist of myostatin that can inc…

  25. 28.

    Wankell M, Munz B, Hübner G, Hans W, Wolf E, Goppelt A, Werner S. · 2001 · PMID 11574468

    Recently, we demonstrated a strong upregulation of activin expression after skin injury. Furthermore, overexpression of this transforming growth factor beta family member in the skin of transgenic mice caused dermal fibrosis, epidermal hyperthickening and enhanced wound repair. However, the role of endogenous activin in wound healing has not been determined. To address this question we overexpressed the soluble activin antagonist follistatin in the epidermis of transgenic mice. These animals wer…

  26. 29.

    Silva RN, Bueno PG, Avó LR, Nonaka KO, Selistre-Araújo HS, Leal AM. · 2014 · PMID 25075578

    Nonalcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in the liver and is associated with obesity and insulin resistance. Activin A is a member of the transforming growth factor beta (TGF)-β superfamily and inhibits hepatocyte growth. Follistatin antagonizes the biological actions of activin. Exercise is an important therapeutic strategy to reduce the metabolic effects of obesity. We evaluated the pattern of activin A and follistatin liver expression in obese rats subject…

  27. 30.

    Iyer CC, Chugh D, Bobbili PJ, Iii AJB, Crum AE, Yi AF, Kaspar BK, Meyer KC, Burghes AHM, Arnold WD. · 2021 · PMID 33964607

    Sarcopenia, or age-related loss of muscle mass and strength, is an important contributor to loss of physical function in older adults. The pathogenesis of sarcopenia is likely multifactorial, but recently the role of neurological degeneration, such as motor unit loss, has received increased attention. Here, we investigated the longitudinal effects of muscle hypertrophy (via overexpression of human follistatin, a myostatin antagonist) on neuromuscular integrity in C57BL/6J mice between the ages o…

  28. 31.

    Panneerselvam P, Sivakumari K, Jayaprakash P, Srikanth R. · 2010 · PMID 21918632

    Follistatin has been reported as a candidate gene for polycystic ovarian syndrome (PCOS) based on linkage and association studies. In this study, investigation of polymorphisms in the FST gene was done to determine if genetic variation is associated with susceptibility to PCOS. The nucleotide sequence of human follistatin and the protein sequence of human follistatin were retrieved from the NCBI database using Entrez. The follistatin protein of human was retrieved from the Swiss-Prot database. T…

  29. 32.

    Kreidl E, Kreidl E, Oztürk D, Metzner T, Berger W, Grusch M. · 2009 · PMID 21160961

    Activins are secreted proteins belonging to the TGF-β family of signaling molecules. Activin signals are crucial for differentiation and regulation of cell proliferation and apoptosis in multiple tissues. Signal transduction by activins relies mainly on the Smad pathway, although the importance of crosstalk with additional pathways is increasingly being recognized. Activin signals are kept in balance by antagonists at multiple levels of the signaling cascade. Among these, follistatin and FLRG, t…

  30. 33.

    Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR. · 2015 · PMID 27858738

    Follistatin is a ubiquitous secretory propeptide that functions as a potent inhibitor of the myostatin pathway, resulting in an increase in skeletal muscle mass. Its ability to interact with the pituitary activin-inhibin axis and suppress the secretion of follicle-stimulating hormone (FSH) called for caution in its clinical applicability. This limitation was circumvented by the use of one of the alternatively spliced follistatin variants, FS344, undergoing post-translational modification to FS31…

  31. 34.

    Refaat B, El-Shemi AG, Ashshi AM. · 2015 · PMID 26112013

    <h4>Background</h4>Activin-A and follistatin regulate the liver and the immune system.<h4>Aims</h4>To measure the effects of treatment with pegylated-interferon-α (Peg-IFN-α) and ribavirin on the concentrations of mature activin-A and follistatin in serum and liver tissue homogenates in rats.<h4>Methods</h4>A total of 28 male Wistar rats were divided equally into four groups as follow: 'Control group' (n = 7), 'PEG only group' consisted of those that only received a weekly injection of Peg-IFN-α…

  32. 35.

    Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK. · 2008 · PMID 18334646

    Increasing the size and strength of muscles represents a promising therapeutic strategy for musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of muscle growth. Various myostatin inhibitor approaches have been identified and tested in models of muscle disease with varying efficacies, depending on the age at which myostatin inhibition occurs. Here, we describe a one-time gene administration of myostatin-inhibitor-proteins to enhance muscle mass and strength in…

  33. 36.

    Refaat B. · 2014 · PMID 25421645

    Embryo implantation is a major prerequisite for the successful establishment of pregnancy. Ectopic implantation outside the intrauterine cavity and the development of ectopic pregnancy (EP) is a major cause of maternal morbidity and occasionally mortality during the first trimester. EP may be induced by failure of tubal transport and/or increased tubal receptivity. Activins, their type II receptors and follistatin have been localised in the human endometrial and tubal epithelium and they are maj…

  34. 37.

    Deli A, Kreidl E, Kreidl E, Santifaller S, Trotter B, Seir K, Berger W, Schulte-Hermann R, Rodgarkia-Dara C, Grusch M. · 2008 · PMID 18350601

    In many parts of the world hepatocellular carcinoma (HCC) is among the leading causes of cancer-related mortality but the underlying molecular pathology is still insufficiently understood. There is increasing evidence that activins, which are members of the transforming growth factor beta (TGFbeta) superfamily of growth and differentiation factors, could play important roles in liver carcinogenesis. Activins are disulphide-linked homo- or heterodimers formed from four different beta subunits ter…

  35. 38.

    Refaat B, El-Shemi AG, Ashshi AM, Mahamid EW, Al-Qadi NM. · 2015 · PMID 26236109

    <h4>Aims</h4>To measure the expression of activin βA-subunit, activin IIA and IIB receptors, Smad4, Smad7, and follistatin in the liver and the liver and serum concentrations of mature activin-A and follistatin in normal rat following treatment with pegylated interferon-α (Peg-INF-α) and ribavirin (RBV).<h4>Materials and methods</h4>40 male Wistar rats were divided equally into 4 groups: "control," "Peg-only" receiving 4 injections of Peg-INF-α (6 µg/rat/week), "RBV-only" receiving ribavirin (4…

  36. 39.

    Fitzgerald AM, Benz C, Clark AF, Wordinger RJ. · 2012 · PMID 23010638

    <h4>Purpose</h4>To compare follistatin (FST) and activin (Act) expression in normal and glaucomatous trabecular meshwork (TM) cells and tissues and determine if exogenous TGF-β2 regulates the expression of FST and Act in TM cells.<h4>Methods</h4>Total RNA was isolated from TM cell strains, and mRNA expression for FST 317/344 isoforms and Act was determined via RT-PCR and quantitative PCR (qPCR). Western immunoblotting and immunocytochemistry determined FST and Act A protein levels in normal TM (…

  37. 40.

    Sharma TP, Nett TM, Karsch FJ, Phillips DJ, Lee JS, Herkimer C, Padmanabhan V. · 2012 · PMID 22423050

    The current dogma is that the differential regulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) synthesis and secretion is modulated by gonadotropin-releasing hormone (GnRH) pulse frequency and by changes in inhibins, activins, and follistatins both at the pituitary and at the peripheral level. To date no studies have looked at the overlapping function of these regulators in a combined setting. We tested the hypothesis that changes in GnRH pulse frequency alter the relat…

  38. 41.

    Bickel D, Shah R, Gesualdi SC, Haerry TE. · 2008 · PMID 18077144

    Follistatin (FS) is one of several secreted proteins that modulate the activity of TGF-beta family members during development. The structural and functional analysis of Drosophila Follistatin (dFS) reveals important differences between dFS and its vertebrate orthologues: it is larger, more positively charged, and proteolytically processed. dFS primarily inhibits signaling of Drosophila Activin (dACT) but can also inhibit other ligands like Decapentaplegic (DPP). In contrast, the presence of dFS…

  39. 42.

    van Schaik RH, Wierikx CD, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, van Steenbrugge GJ, de Jong FH. · 2000 · PMID 10638976

    The possible role of activin in the regulation of malignant prostatic growth was studied using RNAase protection assays of activin receptors, inhibin/activin subunits and follistatin mRNAs in the human prostatic carcinoma cell lines LNCaP-FGC, -R and -LNO, in human prostatic carcinoma xenografts and in human prostatic tissue. Activin receptor types IA (ActRIA), IB (ActRIB), IIA (ActRIIA) and IIB (ActRIIB) mRNAs were generally expressed in prostate epithelial cells, with significantly lower level…

  40. 43.

    Namwanje M, Brown CW. · 2016 · PMID 27328872

    Since their original discovery as regulators of follicle-stimulating hormone (FSH) secretion and erythropoiesis, the TGF-β family members activin and inhibin have been shown to participate in a variety of biological processes, from the earliest stages of embryonic development to highly specialized functions in terminally differentiated cells and tissues. Herein, we present the history, structures, signaling mechanisms, regulation, and biological processes in which activins and inhibins participa…

Curated sources on file

2
  1. 1.
  2. 2.
    Note: Follistatin-315 (FST315) is the major circulating follistatin isoform; cited paper describes parent follistatin / myostatin biology. No isoform-specific clinical trial data available.

Continue reading